Week in Review: China Life Science Books $1 Billion in Ten Announced Deals

Deals and Financings   Sino Biopharm announced a deal worth up to $200 million to acquire a 60% stake in Softhale, a Belgium company with a novel inhaler; Chime Biologics collected $190 million in commitments for an A+ round to expand its CDMO operations in Wuhan BioLake; Hutchison China MediTech signed an agreement to sell its interest in a TCM company with OTC products for $169 million; Brii Biosciences, a Shanghai-US company developing anti-infectives and CNS products for China , completed a $155 million Series C financing; EpimAb of Shanghai raised $120 million in a Series C round for its portfolio of bispecific antibody therapies for oncology; Hangzhou Innoforce Pharma completed a $96 million Series A to support its CRO/CDMO and biomanufacturing services; Shanghai ImmuneOnco Biopharma announced an $89 million Series C funding to develop cancer drugs using macrophages and natural killer cells; Bioheng Biotech of Nanjing raised $80 million in a Series B financing to develop its novel allogeneic CAR-T oncology immunotherapies; XtalPi, a Boston-Shenzhen AI drug discovery company, participated in a $46 million round for PhoreMost, a UK drug discovery company; CASI Pharma, a Maryland-Beijing company, completed a $32.5 million private placement to in-license drugs for China ; Tavotek, a Philadelphia-Suzhou biotech, raised more than $20 million for CMC production and IND filings of its three lead antibody drugs; Zenas BioPharma, a Hong Kong-Boston startup, in-licensed a portfolio of seven candidates for autoimmune and rare diseases; AllianThera Biopharma of Suzhou partnered with Hong Kong 's Insilico to discover molecules for novel cancer and autoimmune targets; Trials and Approvals Citrine Medicine, a Shanghai-Boston rare disease company, received a waiver to market a narcolepsy treatment in China using US/EU data; Beijing 's Eucure Biopharma reported "encouraging" results from an Australian Phase I trial of its anti-CTLA-4 antibody in patients with solid tumor cancers. Stock Symbols: (HK: 1177) (NSDQ/AIM: HCM) (NSDQ: CASI) Share this with colleagues: // //